摘要
目的探索对于经聚乙二醇干扰素-α(PegIFNα)标准疗程治疗而未获得HBeAg血清学转换的慢性乙型肝炎(CHB)患者,延长PegIFNα疗程是否能提高疗效。方法选取PegIFNα治疗48周未能获得HBeAg血清学转换的患者,根据患者的意愿分为2组:A组将PegIFNα疗程延长24周,然后序贯恩替卡韦(ETV)治疗;B组立即改用ETV治疗。观察96周,每12周检测HBV DNA及HBV病毒学标志物。结果 A组在24、48、96周时HBeAg血清学转换率为0.00%、20.83%、25.00%。B组则分别为9.67%、29.03%、48.39%。B组的HBeAg血清学转换率较A组高,但差异无统计学意义(P=0.33、0.49、0.08)。2组在观察期血清HBsAg水平均无明显下降。结论对于经标准疗程PegIFNα治疗而未获得HBeAg血清学转换的CHB患者,延长PegIFNα疗程并未使患者的应答率提高。
Objective To investigate whether prolonged peg-interferon-α (PegIFNα) therapy would improve the efficacy for chronic hepatitis B (CHB) patients who did not achieve HBeAg seroconversion after 48 weeks of PegIFNα treatment. Methods CHB patients with HBeAg-positive who were treated with PegIFNα for 48 weeks and did not reach HBeAg seroconversion were enrolled into 2 groups based on their preferences.Patients in group A received PegIFNα for a further 24 weeks before switching to entecavir (ETV).Patients in group B received ETV.The observation period was 96 weeks.Hepatitis B virus (HBV) DNA and viology markers data were collected every 12 weeks. Results At the end of 24,48,96 weeks,the rate of HBeAg seroconversion in group A were 0.00%,20.83%,25.00% respectively,and those in group B were 9.67 %, 29.03 %,48.39% respectively.The rates of HBeAg seroconversion were higher in group B,but there were no significant differences between the two groups( P =0.33,0.49,0.08).HBsAg in two groups didn′t decrease. Conclusion Patients who don′t achieve HBeAg seroconversion after 48 weeks of PegIFNα therapy,extending the duration of PegIFNα shows no superiority.
作者
舒丹
龚觅
黄湘荣
纪燕华
蒋育进
许诚
SHU Dan;GONG Mi;HUANG Xiangrong;JI Yanhua;JIANG Yujin;XU Cheng(The Third Department of Hepatology;the Institute of Liver Disease,the Third People′s Hospital of Shenzhen,Shenzhen,Guangdong 518112,China)
出处
《检验医学与临床》
CAS
2018年第15期2204-2206,2210,共4页
Laboratory Medicine and Clinic
基金
广东省深圳市科技创新研发资金项目(JCYJ20150402111430634)